PPOIT-003

Peanut is the most common cause of life-threatening allergic reactions, and one of the commonest causes of death from food-induced anaphylaxis. There is currently no effective long-term treatment for food allergy.

We have previously shown that a novel treatment comprising a combination of a probiotic together with peanut allergen oral immunotherapy (PPOIT-001) is highly effective at inducing SU in children with peanut allergy, with benefit persisting to 4 years after treatment cessation in the majority of initial treatment responders. Eighty-two percent (82%) of PPOIT treated participants achieved SU to peanut as compared to only 3.6% of placebo-treated children.

Having demonstrated that PPOIT is highly effective in inducing SU in children with peanut allergy, it is now imperative to examine whether our combined PPOIT treatment is more effective than peanut OIT alone, i.e. whether the addition of probiotic to OIT results in added benefit.

PPOIT-003 is a multicentre, randomised, three-arm, double-blind placebo-controlled phase 2b trial, conducted in 3 children’s hospitals in Australia – the Royal Children’s Hospital Melbourne, Perth Children’s Hospital, and the Women’s and Children’s Hospital in Adelaide.